PsychoPharmacology News
Psychopharmacology: Drugs, the Brain & Behavior explores what medications actually do to the brain—and what the research really says about their benefits, risks, controversies, and unexpected effects. Hosted by psychologist Dr. Carlos Vazquez, each episode examines a medication, drug class, emerging treatment, or provocative new study through the science of pharmacology, neuroscience, and human behavior. From antidepressants, stimulants, antipsychotics, lithium, and anxiety medications to ketamine, psychedelics, addiction treatments, pharmacogenetics, and emerging drugs, the podcast goes beyond headlines to explain mechanisms of action and the evidence behind them. You’ll also hear occasional foundational episodes explaining receptors, neurotransmitters, drug classes, side effe...
10
Why Antidepressants Sometimes Stop Working: The Science Behind the Loss of Response
Antidepressants influence neurotransmission relatively quickly, yet meaningful clinical improvement often takes longer. This episode explores receptor signaling, neural adaptation, stress circuitry, and neuroplasticity in depression treatment. Discover why changes in brain function are more complicated than the familiar chemical-imbalance explanation.
When Antipsychotics Aren’t the Answer: The Medical Illness That Can Look Like Psychosis
Hallucinations, paranoia, agitation, and bizarre behavior can reasonably lead clinicians toward antipsychotic treatment, but what happens when the underlying illness isn’t primarily psychiatric? Anti-NMDA receptor encephalitis can initially resemble a severe psychiatric disorder before neurological symptoms emerge. This episode examines the diagnostic clues that can change the entire treatment strategy.
Why Do SSRIs Take Weeks to Work If They Change Serotonin Within Hours?
SSRIs begin altering serotonin signaling within hours, yet people with depression or anxiety are often told that meaningful improvement may take weeks. Why does the brain respond so slowly if the medication begins working almost immediately? The answer reveals why the familiar idea of antidepressants simply “correcting a chemical imbalance” is far too simplistic. This episode explores serotonin transporters, receptor adaptation, neural plasticity, and the gradual biological changes that may contribute to antidepressant effects. It also explains why an SSRI can be pharmacologically active long before a person notices a meaningful psychological difference.
Beyond the Daily Pill: The Injection Shaking Up Bipolar Treatment
A new study published in The American Journal of Psychiatry analyzed electronic health records from 2,086 individuals with bipolar disorder in Hong Kong treated between 2004 and 2023. While long-acting injectable antipsychotics (LAIAs) are already widely recognized for treating schizophrenia, robust comparative guidance for bipolar disorder has historically been limited. The researchers found that patients receiving LAIAs had a significantly lower risk of psychiatric hospitalization compared to those on traditional oral antipsychotics. In addition, the injectable treatments were tied to a reduced recurrence rate of manic and mixed episodes, offering compelling evidence for their expanded clinical role.
A Simpler Way to Ease OCD When Bipolar Is Also in the Picture
Many people live with both bipolar disorder and obsessive-compulsive symptoms. The usual medicines for OCD can make bipolar moods swing more wildly. A new study points to a different option that may help without that risk.
The FDA Is Fast-Tracking Psychedelics. Noribogaine Is the Test Case That Is Not a Trip.
After an executive order pushing HHS to speed mental-health treatments, the FDA issued priority vouchers for psilocybin in depression and methylone in PTSD and cleared the first U.S. trial of an ibogaine-related drug. That compound is noribogaine, aimed at alcohol use disorder, and its developers argue it is not hallucinogenic. The scientific question is no longer whether Washington is interested. It is whether cardiac risk, blinding, and psychotherapy can survive a real review.
Know Your Brain: The Four Lobes and What They Actually Do
This episode breaks down the brain's four primary lobes — frontal, parietal, temporal, and occipital — and explains, in plain terms, what each one actually does and what happens when it's damaged or atypical. Along the way, the conversation touches on how differences in these brain regions show up in conditions like ADHD and autism spectrum disorder. It's a clear, foundational look at neuroanatomy for anyone curious about the biological side of how we think, feel, and behave.
Psychopharmacology Masterclass: Drug Classes, Mechanisms of Action, and What Every Psychologist Needs to Know for Clinical Practice and the
Psychopharmacology is one of the most heavily tested and clinically consequential domains in professional psychology, covering everything from the neurochemical mechanisms behind antidepressants, antipsychotics, mood stabilizers, and anxiolytics to the pharmacokinetic principles that determine how drugs are absorbed, distributed, metabolized, and eliminated in ways that directly affect treatment outcomes and patient safety. This lecture-style episode breaks down the major drug classes tested on the EPPP and encountered in integrated care settings, including SSRIs, SNRIs, tricyclics, MAOIs, first and second generation antipsychotics, benzodiazepines, and lithium, covering their mechanisms, therapeutic windows, side effect profiles, and the clinical decision-making frameworks psychologists need to...
Retracted: The Hepatitis B Vaccine, Autism Claims, and the Challenges of Causation
In this episode, we examine the recent retraction of a 2010 study that suggested a link between neonatal hepatitis B vaccination and autism in boys. We break down the methodological flaws that led to its withdrawal, explore related research from the same authors and others, and dive into why establishing causal links between vaccines and autism remains extraordinarily complex. Autism is multifactorial—shaped by genetics, environment, and timing—and we discuss the broader scientific consensus while highlighting the importance of rigorous evidence in public health debates.
Escitalopram for Kids’ Anxiety: FDA Approval or Risky Gamble? Weighing the Evidence”
In 2023, the FDA approved escitalopram (Lexapro) for generalized anxiety disorder (GAD) in children aged 7 and older, based largely on one industry-sponsored trial showing a small statistical edge over placebo on the Pediatric Anxiety Rating Scale (PARS). Critics argue the benefits fall below clinically meaningful thresholds while risks—particularly a roughly six-fold increase in treatment-emergent suicidal ideation—raise serious concerns about the risk-benefit balance. This episode explores the trial data, study limitations, broader context of pediatric antidepressant use, and what it means for families and clinicians navigating anxiety treatment options.
